Cancer Research UK logo.
SearchDonate
  • Search

A study looking at blood, urine and tissue samples to help diagnose pancreatic cancer, neuroendocrine tumours of the pancreas and bile duct cancer (ADEPTS)

Overview

Cancer types:

Bile duct cancer, Biliary tree cancers, Neuroendocrine tumour (NET), Pancreatic cancer

Status:

Open

Phase:

Phase 2

Details

In this study, doctors and researchers want to look at blood, urine and tissue samples from people who have symptoms similar to those with:

  • pancreatic cancer

  • neuroendocrine tumours (NETs) of the pancreas

  • bile duct cancer

In most cases such symptoms are caused by many other benign conditions. But it is important to make sure that those that are due to cancer, are diagnosed early. They hope the results of this study will help them develop new tests to diagnose pancreatic cancer and NETs of the pancreas at an early stage. This study was formerly known as TRANSBIL.

Recruitment start: 1 June 2018

Recruitment end: 1 March 2026

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Stephen Pereira

Supported by

UCLH Cancer Collaborative

Pancreatic Cancer UK

Fiorina Pancreatic Cancer Fund (Royal Free Charity)

NIHR Clinical Research Network: North Thames

Last reviewed: 12 September 2025

CRUK internal database number: 15401

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.